SGO 2023 Conference Coverage on VuMedi


 

SGO 2023 Phase 3 UP-NEXT Trial: Upifitamab Rilsodotin, a NaPi2b-Directed ADC, in Platinum-Sensitive Recurrent Ovarian Cancer

117 views
April 14, 2023
Comments 0
Login to view comments. Click here to Login